Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 22 | 2024 | 394 | 6.700 |
Why?
|
| Cell-Free Nucleic Acids | 4 | 2024 | 82 | 3.120 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 258 | 2.410 |
Why?
|
| 5-Methylcytosine | 3 | 2024 | 113 | 1.710 |
Why?
|
| Sarcoma, Ewing | 4 | 2014 | 44 | 1.670 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 328 | 1.560 |
Why?
|
| Osteosarcoma | 2 | 2023 | 160 | 1.010 |
Why?
|
| Child | 18 | 2024 | 7089 | 0.960 |
Why?
|
| Child, Preschool | 15 | 2024 | 3678 | 0.930 |
Why?
|
| Prognosis | 12 | 2024 | 3750 | 0.920 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1520 | 0.910 |
Why?
|
| Infant | 13 | 2024 | 3117 | 0.830 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2021 | 20 | 0.810 |
Why?
|
| Pediatrics | 3 | 2021 | 351 | 0.750 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.740 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 33 | 0.700 |
Why?
|
| Oncologists | 1 | 2019 | 36 | 0.680 |
Why?
|
| Machine Learning | 1 | 2021 | 242 | 0.680 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 1256 | 0.670 |
Why?
|
| Epigenomics | 1 | 2019 | 103 | 0.660 |
Why?
|
| Fathers | 1 | 2019 | 70 | 0.660 |
Why?
|
| Inflammation | 1 | 2024 | 961 | 0.640 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 312 | 0.640 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1221 | 0.610 |
Why?
|
| Neoplasms | 5 | 2023 | 3009 | 0.600 |
Why?
|
| Humans | 39 | 2024 | 88611 | 0.550 |
Why?
|
| Adolescent | 13 | 2022 | 9157 | 0.540 |
Why?
|
| DNA Methylation | 2 | 2022 | 656 | 0.530 |
Why?
|
| Survivors | 2 | 2016 | 233 | 0.530 |
Why?
|
| Young Adult | 11 | 2022 | 6218 | 0.470 |
Why?
|
| Hypoxia | 3 | 2023 | 650 | 0.460 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2011 | 129 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 205 | 0.440 |
Why?
|
| Radiation Injuries | 1 | 2014 | 160 | 0.440 |
Why?
|
| Transition to Adult Care | 1 | 2013 | 22 | 0.430 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.430 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 26 | 0.430 |
Why?
|
| Medical Informatics | 1 | 2013 | 48 | 0.420 |
Why?
|
| Radiotherapy | 1 | 2014 | 331 | 0.420 |
Why?
|
| Genomics | 2 | 2022 | 747 | 0.410 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2011 | 6 | 0.410 |
Why?
|
| Methyltransferases | 2 | 2024 | 192 | 0.410 |
Why?
|
| Patient Preference | 1 | 2013 | 108 | 0.400 |
Why?
|
| Male | 16 | 2024 | 42012 | 0.400 |
Why?
|
| Female | 19 | 2024 | 45759 | 0.380 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 539 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 782 | 0.360 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 38 | 0.360 |
Why?
|
| Apoptosis | 3 | 2023 | 1718 | 0.360 |
Why?
|
| Aging | 1 | 2014 | 712 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 865 | 0.310 |
Why?
|
| Models, Biological | 2 | 2016 | 1764 | 0.310 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 858 | 0.280 |
Why?
|
| Adult | 10 | 2022 | 26348 | 0.270 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 78 | 0.260 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2445 | 0.250 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 2538 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2021 | 376 | 0.250 |
Why?
|
| Risk Factors | 4 | 2021 | 5449 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1213 | 0.230 |
Why?
|
| Signal Transduction | 1 | 2014 | 3368 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2021 | 2837 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2023 | 24 | 0.220 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 149 | 0.220 |
Why?
|
| SEER Program | 2 | 2014 | 197 | 0.220 |
Why?
|
| Teratoma | 1 | 2023 | 51 | 0.210 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 48 | 0.210 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 269 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 111 | 0.210 |
Why?
|
| Mixed Function Oxygenases | 1 | 2022 | 69 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 43 | 0.210 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2023 | 43 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 478 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2024 | 1647 | 0.200 |
Why?
|
| Gene Amplification | 2 | 2023 | 133 | 0.200 |
Why?
|
| Survival Rate | 3 | 2020 | 1883 | 0.200 |
Why?
|
| Histones | 1 | 2024 | 327 | 0.200 |
Why?
|
| Research Report | 1 | 2021 | 43 | 0.200 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 85 | 0.190 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 221 | 0.190 |
Why?
|
| Incidence | 2 | 2016 | 1592 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 322 | 0.180 |
Why?
|
| Glioma | 1 | 2023 | 291 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2322 | 0.180 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 57 | 0.180 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1983 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1709 | 0.180 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 6 | 0.180 |
Why?
|
| Intergenerational Relations | 1 | 2019 | 5 | 0.180 |
Why?
|
| Bayes Theorem | 1 | 2021 | 368 | 0.180 |
Why?
|
| Pleura | 1 | 2020 | 31 | 0.170 |
Why?
|
| Back Pain | 1 | 2019 | 42 | 0.170 |
Why?
|
| Family Relations | 1 | 2019 | 35 | 0.170 |
Why?
|
| Age Factors | 2 | 2021 | 1863 | 0.170 |
Why?
|
| Naphthyridines | 1 | 2019 | 27 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 661 | 0.160 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1518 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2021 | 1542 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1352 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 2536 | 0.140 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.140 |
Why?
|
| Palmitic Acid | 1 | 2016 | 28 | 0.140 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.140 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8893 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 759 | 0.140 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 253 | 0.140 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.130 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 837 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 200 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1096 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 884 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.130 |
Why?
|
| DNA Repair | 1 | 2016 | 359 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2022 | 8178 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 193 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 697 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2014 | 226 | 0.110 |
Why?
|
| Computational Biology | 1 | 2016 | 542 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 665 | 0.110 |
Why?
|
| Consumer Health Information | 1 | 2013 | 14 | 0.110 |
Why?
|
| Focus Groups | 1 | 2013 | 164 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2016 | 2286 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3655 | 0.100 |
Why?
|
| Transcriptome | 1 | 2016 | 623 | 0.100 |
Why?
|
| Self Care | 1 | 2013 | 164 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2013 | 285 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 9 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 204 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 1063 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1427 | 0.090 |
Why?
|
| Heterografts | 2 | 2023 | 102 | 0.090 |
Why?
|
| Patient Participation | 1 | 2013 | 224 | 0.090 |
Why?
|
| Disease Management | 1 | 2013 | 328 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2746 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 499 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 1095 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 948 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2011 | 269 | 0.080 |
Why?
|
| Cell Hypoxia | 2 | 2022 | 170 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2879 | 0.080 |
Why?
|
| International Cooperation | 2 | 2020 | 124 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1694 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 11710 | 0.070 |
Why?
|
| Cell Movement | 2 | 2022 | 784 | 0.070 |
Why?
|
| Middle Aged | 2 | 2014 | 25699 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 4271 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2023 | 507 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 6723 | 0.050 |
Why?
|
| Adenosine | 1 | 2024 | 238 | 0.050 |
Why?
|
| Animals | 4 | 2024 | 27233 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 176 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 342 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2023 | 814 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 421 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 20 | 0.050 |
Why?
|
| Mitosis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 283 | 0.040 |
Why?
|
| Cough | 1 | 2020 | 55 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 75 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 699 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 237 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 367 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 407 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 68 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 684 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
| Aged | 1 | 2012 | 18932 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 311 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 390 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 980 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 179 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2016 | 369 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1851 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4097 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1709 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1662 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2399 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5319 | 0.020 |
Why?
|